Constitutive Gs-mediated, but not G12-mediated, activity of the 5-hydroxytryptamine 5-HT7(a) receptor is modulated by the palmitoylation of its C-terminal domain

Biochimica et Biophysica Acta - Molecular Cell Research

Volumn 1793, Issue 11, 2009, Pages 1646-1655

  Kvachnina, Elena ^a   Dumuis, Aline ^b   Wlodarczyk, Jakub ^c,d   Renner, Ute ^a,e   Cochet, Maud ^b   Richter, Diethelm W ^a,e   Ponimaskin, Evgeni ^d,f  

^a UNIVERSITY OF GÖTTINGEN   (Germany)

^b CNRS   (France)

^c MAX PLANCK INSTITUTE FOR BIOPHYSICAL CHEMISTRY   (Germany)

^d NENCKI INSTITUTE OF EXPERIMENTAL BIOLOGY   (Poland)

^e Deutsche Forschungsgemeinschaft   (Germany)

^f HANNOVER MEDICAL SCHOOL   (Germany)

Author keywords

5 Hydroxytriptamine; G protein coupled receptor; Heterotrimeric G protein; Palmitoylation

Indexed keywords

CYSTEINE; FATTY ACID; GUANINE NUCLEOTIDE BINDING PROTEIN; PALMITIC ACID; PROTEIN; SERINE; SEROTONIN 7A RECEPTOR; SEROTONIN RECEPTOR; THIOESTER; UNCLASSIFIED DRUG; GUANINE NUCLEOTIDE BINDING PROTEIN ALPHA SUBUNIT; PALMITIC ACID DERIVATIVE; SEROTONIN 7 RECEPTOR; STIMULATORY GUANINE NUCLEOTIDE BINDING PROTEIN;

ANIMAL CELL; ARTICLE; BRAIN CORTEX; CARBOXY TERMINAL SEQUENCE; CELL LABELING; CONTROLLED STUDY; COVALENT BOND; HIPPOCAMPUS; HYPOTHALAMUS; MUTATIONAL ANALYSIS; NONHUMAN; PALMITOYLATION; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN PROCESSING; SIGNAL TRANSDUCTION; THALAMUS; ANIMAL; CELL LINE; GENETICS; LIPOYLATION; METABOLISM; MOUSE; PHYSIOLOGY; PROTEIN TERTIARY STRUCTURE;

ANIMALS; CELL LINE; GTP-BINDING PROTEIN ALPHA SUBUNITS, G12-G13; GTP-BINDING PROTEIN ALPHA SUBUNITS, GS; LIPOYLATION; MICE; PALMITIC ACIDS; PROTEIN STRUCTURE, TERTIARY; RECEPTORS, SEROTONIN; SIGNAL TRANSDUCTION;

EID: 71749087889     PISSN: 01674889     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bbamcr.2009.08.008     Document Type: Article

References (57)

1. Barnes N.M., and Sharp T. A review of central 5-HT receptors and their function. Neuropharmacology 38 (1999) 1083-1152
2. Bockaert J., Claeysen S., Becamel C., Dumuis A., and Marin P. Neuronal 5-HT metabotropic receptors: fine-tuning of their structure, signaling, and roles in synaptic modulation. Cell Tissue Res. 326 (2006) 553-572
3. Hedlund P.B., and Sutcliffe J.G. Functional, molecular and pharmacological advances in 5-HT7 receptor research. Trends Pharmacol. Sci. 25 (2004) 481-486
4. Norum J.H., Hart K., and Levy F.O. Ras-dependent ERK activation by the human G(s)-coupled serotonin receptors 5-HT4(b) and 5-HT7(a). J. Biol. Chem. 278 (2003) 3098-3104
5. Kvachnina E., Liu G., Dityatev A., Renner U., Dumuis A., Richter D.W., Dityateva G., Schachner M., Voyno-Yasenetskaya T.A., and Ponimaskin E.G. 5-HT7 receptor is coupled to G alpha subunits of heterotrimeric G12-protein to regulate gene transcription and neuronal morphology. J. Neurosci. 25 (2005) 7821-7830
6. Lovenberg T.W., Baron B.M., de Lecea L., Miller J.D., Prosser R.A., Rea M.A., Foye P.E., Racke M., Slone A.L., Siegel B.W., et al. A novel adenylyl cyclase-activating serotonin receptor (5-HT7) implicated in the regulation of mammalian circadian rhythms. Neuron. 11 (1993) 449-458
7. Duncan M.J., Short J., and Wheeler D.L. Comparison of the effects of aging on 5-HT7 and 5-HT1A receptors in discrete regions of the circadian timing system in hamsters. Brain Res. 829 (1999) 39-45
8. Thomas D.R., Melotto S., Massagrande M., Gribble A.D., Jeffrey P., Stevens A.J., Deeks N.J., Eddershaw P.J., Fenwick S.H., Riley G., Stean T., Scott C.M., Hill M.J., Middlemiss D.N., Hagan J.J., Price G.W., and Forbes I.T. SB-656104-A, a novel selective 5-HT7 receptor antagonist, modulates REM sleep in rats. Br. J. Pharmacol. 139 (2003) 705-714
9. Hedlund P.B., Danielson P.E., Thomas E.A., Slanina K., Carson M.J., and Sutcliffe J.G. No hypothermic response to serotonin in 5-HT7 receptor knockout mice. Proc. Natl. Acad Sci. U. S. A. 100 (2003) 1375-1380
10. Terron J.A. Involvement of the 5-HT7 receptor in craniovascular vasodilatation: potential impact in migraine. Proc. West Pharmacol. Soc. 41 (1998) 247-251
11. Patterson S.I. Posttranslational protein S-palmitoylation and the compartmentalization of signaling molecules in neurons. Biol. Res. 35 (2002) 139-150
12. el-Husseini Ael D., and Bredt D.S. Protein palmitoylation: a regulator of neuronal development and function. Nat. Rev., Neurosci. 3 (2002) 791-802
13. Smotrys J.E., and Linder M.E. Palmitoylation of intracellular signaling proteins: regulation and function. Annu. Rev. Biochem. 73 (2004) 559-587
14. Escriba P.V., Wedegaertner P.B., Goni F.M., and Vogler O. Lipid-protein interactions in GPCR-associated signaling. Biochim. Biophys. Acta 1768 (2007) 836-852
15. Torrecilla I., and Tobin A.B. Co-ordinated covalent modification of G-protein coupled receptors. Curr. Pharm. Des. 12 (2006) 1797-1808
16. Chini B., and Parenti M. G-protein-coupled receptors, cholesterol and palmitoylation: facts about fats. J. Mol. Endocrinol. 42 (2009) 371-379
17. Resh M.D. Palmitoylation of ligands, receptors, and intracellular signaling molecules. Sci. STKE (2006) re14
18. Qanbar R., and Bouvier M. Role of palmitoylation/depalmitoylation reactions in G-protein-coupled receptor function. Pharmacol. Ther. 97 (2003) 1-33
19. Ponimaskin E.G., Schmidt M.F., Heine M., Bickmeyer U., and Richter D.W. 5-Hydroxytryptamine 4(a) receptor expressed in Sf9 cells is palmitoylated in an agonist-dependent manner. Biochem. J. 353 (2001) 627-634
20. Papoucheva E., Dumuis A., Sebben M., Richter D.W., and Ponimaskin E.G. The 5-hydroxytryptamine(1A) receptor is stably palmitoylated, and acylation is critical for communication of receptor with Gi protein. J. Biol. Chem. 279 (2004) 3280-3291
21. Ponimaskin E., Dumuis A., Gaven F., Barthet G., Heine M., Glebov K., Richter D.W., and Oppermann M. Palmitoylation of the 5-hydroxytryptamine(4a) receptor regulates receptor phosphorylation, desensitization and {beta}arrestin mediated endocytosis. Mol. Pharmacol. (2005)
22. Ponimaskin E.G., Heine M., Joubert L., Sebben M., Bickmeyer U., Richter D.W., and Dumuis A. The 5-hydroxytryptamine(4a) receptor is palmitoylated at two different sites, and acylation is critically involved in regulation of receptor constitutive activity. J. Biol. Chem. 277 (2002) 2534-2546
23. In: Sambrook J., Fritsch E., and Maniatis T. (Eds). Molecular cloning: a laboratory manual. 2 ed. (1989), Cold Spring Harbour Laboratory Press, Cold Spring Harbour, NY
24. Ponimaskin E., Harteneck C., Schultz G., and Schmidt M.F. A cysteine-11 to serine mutant of G alpha12 impairs activation through the thrombin receptor. FEBS Lett. 429 (1998) 370-374
25. Ponimaskin E., Behn H., Adarichev V., Voyno-Yasenetskaya T.A., Offermanns S., and Schmidt M.F. Acylation of Galpha(13) is important for its interaction with thrombin receptor, transforming activity and actin stress fiber formation. FEBS Lett. 478 (2000) 173-177
26. Dumuis A., Bouhelal R., Sebben M., and Bockaert J. A 5-HT receptor in the central nervous system, positively coupled with adenylate cyclase, is antagonized by ICS 205 930. Eur. J. Pharmacol. 146 (1988) 187-188
27. Claeysen S., Sebben M., Becamel C., Eglen R.M., Clark R.D., Bockaert J., and Dumuis A. Pharmacological properties of 5-hydroxytryptamine(4) receptor antagonists on constitutively active wild-type and mutated receptors. Mol. Pharmacol. 58 (2000) 136-144
28. Lovell P.J., Bromidge S.M., Dabbs S., Duckworth D.M., Forbes I.T., Jennings A.J., King F.D., Middlemiss D.N., Rahman S.K., Saunders D.V., Collin L.L., Hagan J.J., Riley G.J., and Thomas D.R. A novel, potent, and selective 5-HT(7) antagonist: (R)-3-(2-(2-(4-methylpiperidin-1-yl)ethyl)pyrrolidine-1-sulfonyl)phenol (SB-269970). J. Med. Chem. 43 (2000) 342-345
29. Mahe C., Loetscher E., Feuerbach D., Muller W., Seiler M.P., and Schoeffter P. Differential inverse agonist efficacies of SB-258719, SB-258741 and SB-269970 at human recombinant serotonin 5-HT7 receptors. Eur. J. Pharmacol. 495 (2004) 97-102
30. Skene J.H., and Virag I. Posttranslational membrane attachment and dynamic fatty acylation of a neuronal growth cone protein, GAP-43. J. Cell Biol. 108 (1989) 613-624
31. Linder M.E., Middleton P., Hepler J.R., Taussig R., Gilman A.G., and Mumby S.M. Lipid modifications of G proteins: alpha subunits are palmitoylated. Proc. Natl. Acad Sci. U. S. A. 90 (1993) 3675-3679
32. Wedegaertner P.B., Chu D.H., Wilson P.T., Levis M.J., and Bourne H.R. Palmitoylation is required for signaling functions and membrane attachment of Gq alpha and Gs alpha. J. Biol. Chem. 268 (1993) 25001-25008
33. Robinson L.J., Busconi L., and Michel T. Agonist-modulated palmitoylation of endothelial nitric oxide synthase. J. Biol. Chem. 270 (1995) 995-998
34. Magee A.I., Gutierrez L., Marshall C.J., and Hancock J.F. Targeting of oncoproteins to membranes by fatty acylation. J. Cell Sci., Suppl. 11 (1989) 149-160
35. Wedegaertner P.B., and Bourne H.R. Activation and depalmitoylation of Gs alpha. Cell 77 (1994) 1063-1070
36. Wedegaertner P.B. Lipid modifications and membrane targeting of G alpha. Biol. Signals Recept. 7 (1998) 125-135
37. Liu J., Garcia-Cardena G., and Sessa W.C. Biosynthesis and palmitoylation of endothelial nitric oxide synthase: mutagenesis of palmitoylation sites, cysteines-15 and/or -26, argues against depalmitoylation-induced translocation of the enzyme. Biochemistry 34 (1995) 12333-12340
38. Kang R., Wan J., Arstikaitis P., Takahashi H., Huang K., Bailey A.O., Thompson J.X., Roth A.F., Drisdel R.C., Mastro R., Green W.N., Yates Iii J.R., Davis N.G., and El-Husseini A. Neural palmitoyl-proteomics reveals dynamic synaptic palmitoylation. Nature 456 (2008) 904-909
39. Roth A.F., Wan J., Bailey A.O., Sun B., Kuchar J.A., Green W.N., Phinney B.S., Yates 3rd J.R., and Davis N.G. Global analysis of protein palmitoylation in yeast. Cell 125 (2006) 1003-1013
40. Kennedy M.E., and Limbird L.E. Palmitoylation of the alpha 2A-adrenergic receptor. Analysis of the sequence requirements for and the dynamic properties of alpha 2A-adrenergic receptor palmitoylation. J. Biol. Chem. 269 (1994) 31915-31922
41. Bouvier M., Chidiac P., Hebert T.E., Loisel T.P., Moffett S., and Mouillac B. Dynamic palmitoylation of G-protein-coupled receptors in eukaryotic cells. Methods Enzymol. 250 (1995) 300-314
42. Ng G.Y., Mouillac B., George S.R., Caron M., Dennis M., Bouvier M., and O'Dowd B.F. Desensitization, phosphorylation and palmitoylation of the human dopamine D1 receptor. Eur. J. Pharmacol. 267 (1994) 7-19
43. Loisel T.P., Adam L., Hebert T.E., and Bouvier M. Agonist stimulation increases the turnover rate of beta 2AR-bound palmitate and promotes receptor depalmitoylation. Biochemistry 35 (1996) 15923-15932
44. Hayashi M.K., and Haga T. Palmitoylation of muscarinic acetylcholine receptor m2 subtypes: reduction in their ability to activate G proteins by mutation of a putative palmitoylation site, cysteine 457, in the carboxyl-terminal tail. Arch. Biochem. Biophys. 340 (1997) 376-382
45. Eason M.G., Jacinto M.T., Theiss C.T., and Liggett S.B. The palmitoylated cysteine of the cytoplasmic tail of alpha 2A-adrenergic receptors confers subtype-specific agonist-promoted downregulation. Proc. Natl. Acad Sci. U. S. A. 91 (1994) 11178-11182
46. Okamoto Y., Ninomiya H., Tanioka M., Sakamoto A., Miwa S., and Masaki T. Palmitoylation of human endothelinB. Its critical role in G protein coupling and a differential requirement for the cytoplasmic tail by G protein subtypes. J. Biol. Chem. 272 (1997) 21589-21596
47. Zhu H., Wang H., and Ascoli M. The lutropin/choriogonadotropin receptor is palmitoylated at intracellular cysteine residues. Mol. Endocrinol. 9 (1995) 141-150
48. Sadeghi H.M., Innamorati G., Dagarag M., and Birnbaumer M. Palmitoylation of the V2 vasopressin receptor. Mol. Pharmacol. 52 (1997) 21-29
49. Costa T., and Herz A. Antagonists with negative intrinsic activity at delta opioid receptors coupled to GTP-binding proteins. Proc. Natl. Acad Sci. U. S. A. 86 (1989) 7321-7325
50. Cotecchia S., Exum S., Caron M.G., and Lefkowitz R.J. Regions of the alpha 1-adrenergic receptor involved in coupling to phosphatidylinositol hydrolysis and enhanced sensitivity of biological function. Proc. Natl. Acad Sci. U. S. A. 87 (1990) 2896-2900
51. Smit M.J., Vischer H.F., Bakker R.A., Jongejan A., Timmerman H., Pardo L., and Leurs R. Pharmacogenomic and structural analysis of constitutive G protein-coupled receptor activity. Annu. Rev. Pharmacol. Toxicol. 47 (2007) 53-87
52. Seifert R., and Wenzel-Seifert K. Constitutive activity of G-protein-coupled receptors: cause of disease and common property of wild-type receptors. Naunyn- Schmiedeberg's Arch. Pharmacol. 366 (2002) 381-416
53. Heidmann D.E., Metcalf M.A., Kohen R., and Hamblin M.W. Four 5-hydroxytryptamine7 (5-HT7) receptor isoforms in human and rat produced by alternative splicing: species differences due to altered intron-exon organization. J. Neurochem. 68 (1997) 1372-1381
54. Thomas D.R., Gittins S.A., Collin L.L., Middlemiss D.N., Riley G., Hagan J., Gloger I., Ellis C.E., Forbes I.T., and Brown A.M. Functional characterisation of the human cloned 5-HT7 receptor (long form); antagonist profile of SB-258719. Br. J. Pharmacol. 124 (1998) 1300-1306
55. Claeysen S., Sebben M., Becamel C., Bockaert J., and Dumuis A. Novel brain-specific 5-HT4 receptor splice variants show marked constitutive activity: role of the C-terminal intracellular domain. Mol. Pharmacol. 55 (1999) 910-920
56. Claeysen S., Sebben M., Becamel C., Parmentier M.L., Dumuis A., and Bockaert J. Constitutively active mutants of 5-HT4 receptors: are they in unique active states?. EMBO Rep. 2 (2001) 61-67
57. Krobert K.A., and Levy F.O. The human 5-HT7 serotonin receptor splice variants: constitutive activity and inverse agonist effects. Br. J. Pharmacol. 135 (2002) 1563-1571